Switch theme
Sign up to access all valuation multiples
Changchun High-Tech Industry (Group) Co Ltd is engaged in the production and sales of biopharmaceuticals, Chinese patent medicine production, and real estate development.
1993
2.1K+
LTM Revenue n/a
LTM EBITDA n/a
$4.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Changchun High-Tech has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Changchun High-Tech achieved revenue of $2.0B and an EBITDA of $840M.
Changchun High-Tech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Changchun High-Tech valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.0B | n/a | XXX | XXX | XXX |
| Gross Profit | $1.3B | $1.5B | XXX | XXX | XXX |
| Gross Margin | 65% | NaN% | XXX | XXX | XXX |
| EBITDA | $840M | n/a | XXX | XXX | XXX |
| EBITDA Margin | 42% | NaN% | XXX | XXX | XXX |
| Net Profit | $518M | $570M | XXX | XXX | XXX |
| Net Margin | 26% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Changchun High-Tech's stock price is CNY 98 (or $14).
Changchun High-Tech has current market cap of CNY 40.1B (or $5.5B), and EV of CNY 35.2B (or $4.8B).
See Changchun High-Tech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.8B | $5.5B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Changchun High-Tech has market cap of $5.5B and EV of $4.8B.
Changchun High-Tech's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Changchun High-Tech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Changchun High-Tech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $4.8B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpChangchun High-Tech's NTM/LTM revenue growth is n/a
Changchun High-Tech's revenue per employee for the last fiscal year averaged $0.9M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Changchun High-Tech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Changchun High-Tech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Changchun High-Tech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.9M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 19% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 46% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Changchun High-Tech acquired XXX companies to date.
Last acquisition by Changchun High-Tech was XXXXXXXX, XXXXX XXXXX XXXXXX . Changchun High-Tech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Changchun High-Tech founded? | Changchun High-Tech was founded in 1993. |
| Where is Changchun High-Tech headquartered? | Changchun High-Tech is headquartered in China. |
| How many employees does Changchun High-Tech have? | As of today, Changchun High-Tech has 2.1K+ employees. |
| Is Changchun High-Tech publicy listed? | Yes, Changchun High-Tech is a public company listed on SHE. |
| What is the stock symbol of Changchun High-Tech? | Changchun High-Tech trades under 000661 ticker. |
| When did Changchun High-Tech go public? | Changchun High-Tech went public in 1996. |
| Who are competitors of Changchun High-Tech? | Similar companies to Changchun High-Tech include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Changchun High-Tech? | Changchun High-Tech's current market cap is $5.5B |
| Is Changchun High-Tech profitable? | Yes, Changchun High-Tech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
